Breaks Categories: Analyst Alerts

TuesdayMay 09, 2017 11:51 am

NetworkNewsBreaks – SeeThruEquity Updates Coverage, $10.50 PT on IEG Holdings Corp. (IEGH)

SeeThruEquity has issued a company update and maintained its price target of $10.50 on shares of IEG Holdings Corp. (OTCQB: IEGH). Among other highlights, the analyst notes the company’s recently reported financial results for the first quarter of 2017. The report showed a decrease in operating costs to $1.5 million and revenues of $0.47 million. The company reported that cumulative loan volume was $14.24 million at the end of the first quarter, which the analyst said is of importance as a driver of revenue and potential profitability. The company’s upcoming catalysts include growth, guidance for adjusted profitability this year, and…

Continue Reading

FridayMay 05, 2017 12:15 pm

NetworkNewsBreaks – SeeThruEquity Updates Coverage on Yangtze River Development Ltd. (NASDAQ: YERR), Raises PT to $13.25

SeeThruEquity recently issued a company update and raised its price target to $13.25 on shares of Yangtze River Development Ltd. (NASDAQ: YERR). Among other highlights, the analyst notes the company’s uplisting to the Nasdaq Capital Market on April 19, 2017. The analyst believes this demonstrates a successful execution of a significant corporate milestone, and delivers on management's goals from 2016. For more information, visit www.yerr.com.cn About Yangtze River Development Limited Yangtze River Development Limited primarily engages in the business of real estate development with a port logistic project located in the middle reaches of the Yangtze River. Wuhan Newport is a…

Continue Reading

ThursdayMay 04, 2017 1:25 pm

NetworkNewsBreaks – Aegis Capital Maintains ‘Buy’ Rating on Concert Pharmaceuticals, Inc. (NASDAQ: CNCE)

Aegis Capital has reiterated a ‘Buy’ rating and issued a price target of $25 on shares of Concert Pharmaceuticals, Inc.’s (NASDAQ: CNCE) stock. The news follows the company’s recently reported financial results for the first quarter of 2017, including revenue of $20,000 for the quarter. The analyst noted that because Concert is a clinical stage development company, the firm focuses less on the quarterly financials and more on events surrounding clinical trials and deal announcements. During the first quarter, Concert entered an asset purchase agreement with Vertex Pharmaceuticals (NASDAQ: VRTX) for CTP-656. Per the agreement, Vertex will pay Concert up…

Continue Reading

ThursdayMay 04, 2017 1:23 pm

NetworkNewsBreaks – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) Reiterated with ‘Buy’ at Aegis Capital

Aegis Capital has reiterated a ‘Buy’ rating and price target of $63 on Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) following the company’s recent financial results for the first quarter ended March 31, 2017. The company reported that cash, cash equivalents, and investments at the end of the quarter totaled $207.9 million. The analyst noted that because Aerie is a clinical stage development company, the firm is more focused on upcoming catalysts than quarterly financials. Catalysts for the company include the completion of the Rocket 4 trial; the upcoming Mercury 2 three-month efficacy and safety readout for Roclatan that is expected in…

Continue Reading

ThursdayMay 04, 2017 1:20 pm

NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating on Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA)

Following Vanda Pharmaceuticals, Inc.’s (NASDAQ: VNDA) first quarter 2017 results, Aegis Capital has reiterated its ‘Buy’ rating and price target of $24 on shares of the company’s stock. The company reported net product sales of $37.4 million in the first quarter of 2017 and reaffirmed its net product sales guidance for 2017 of $165 million to $175 million. The Aegis analyst noted that the company has expanded its sales team for Fanapt®, which should drive growth in the third and fourth quarter of this year. Data from three trials that the analyst cited as catalysts for the year is also…

Continue Reading

ThursdayMay 04, 2017 1:19 pm

NetworkNewsBreaks – Aegis Capital Issues ‘Buy’ Rating on Soligenix, Inc. (NASDAQ: SNGX)

Aegis Capital has issued a ‘Buy’ rating and price target of $7 on shares of Soligenix, Inc.’s (NASDAQ: SNGX) stock. The analyst cites the recent approval by the FDA to advance a pivotal phase 3 clinical trial evaluating SGX942 for the treatment of oral mucositis in head and neck cancer (HNC) patients being treated with chemoradiation (CRT). Soligenix plans to initiate this study in the second quarter of 2017. The analyst also noted the company has recently reached important milestones in its development of a vaccine against ricin poisoning, with several data presentations from animal models. For more information, visit…

Continue Reading

WednesdayMay 03, 2017 1:51 pm

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating, $28 PT on Revance Therapeutics, Inc. (NASDAQ: RVNC)

Aegis Capital has reiterated a ‘Buy’ rating and price target of $28 on Revance Therapeutics, Inc. (NASDAQ: RVNC) after the company issued a protocol update on its phase 2 plantar fasciitis (PF) trial. Revance said it has expanded the phase 2 trial to a multi-center protocol with three centers, and changes were also made to the trial’s primary and secondary endpoints. The American Orthopaedic Foot and Ankle Score (AOFAS) will now be the secondary endpoint to provide foot functionality data. The new primary endpoint will be visual analog scale (VAS), which should provide foot pain data. Revance said it expects…

Continue Reading

WednesdayMay 03, 2017 1:48 pm

NetworkNewsBreaks – Aegis Capital Issues “Buy” Rating, $31 PT on Neurotrope, Inc. (NASDAQ: NTRP)

Aegis Capital this week issued a ‘Buy’ rating and price target of $31 on shares of Neurotrope, Inc.’s (NASDAQ: NTRP) stock. The company recently released positive top-line results from its phase 2 study of Bryostatin-1 in patients with moderate to severe Alzheimer's disease (AD). Results from the study demonstrate that AD patients receiving Bryostatin-1 had an improvement in their cognitive abilities compared with a decline in the placebo patients. Aegis analyst Robert LeBoyer said he believes that the study met its objective of showing that Bryostatin-1 has adequate activity and data to move forward into a bigger study with a longer…

Continue Reading

WednesdayMay 03, 2017 11:43 am

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating, Raises PT by $4 on Akebia Therapeutics, Inc. (NASDAQ: AKBA)

Aegis Capital recently reiterated a ‘Buy’ rating and raised the price target to $25 on Akebia Therapeutics, Inc.’s (NASDAQ: AKBA) stock. The action followed the company’s recent expansion of its collaboration with Otsuka Pharmaceutical for vadadustat by entering into a collaboration and license agreement to include China, Europe, Russia, the Middle East, Canada and Australia. Akebia still maintains 50% of the U.S rights, all of Latin America, and control of the development program which includes manufacturing. The analyst noted that the expanded agreement is positive for Akebia, as it addresses the company’s cash needs moving forward, as well as lightening…

Continue Reading

TuesdayMay 02, 2017 1:08 pm

NetworkNewsBreaks – ROTH Capital Partners Performs as Sole Placement Agent for BioPharmX Corp.’s (NYSE: BPMX) $5M Registered Direct Offering

BioPharmX (NYSE: BPMX) has successfully completed a sale of 6,410,258 shares of common stock at a price of $0.78 per share with 50% warrant coverage, representing warrants to purchase up to 3,205,129 shares of common stock, in a registered direct offering. ROTH Capital Partners acted as sole placement agent in the offering. Beginning six months following the closing date, the warrants will be exercisable at an exercise price of $0.90 per share and will expire five years from the date they become exercisable. Gross proceeds of the offering are anticipated to be approximately $5.0 million. The specialty pharmaceutical company said…

Continue Reading